Reporte zur Charge GH970205309

Symptomtext

COVID-19; COVID-19; Moderna, Dose: 1-4 / Pfizer, Dose: 5; This is a spontaneous report received from a contactable reporter(s) (Physician). The reporter is the patient. A 64-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 16Sep2022 at 17:00 as dose 5 (booster), single (Lot number: GH970205309) at the age of 64 years for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 06Jan2021 at 12:00 as dose 1, single (Lot number: 037K20a), on 03Feb2021 at 15:00 as dose 2, single (Lot number: 013M20A), on 30Oct2021 at 16:00 as dose 3 (booster), single (Lot number: 039F21A) and on 20May2022 at 17:00 as dose 4 (booster), single (Lot number: 0J8A22A) for covid-19 immunisation. The patient's relevant medical history included: "HTN" (unspecified if ongoing); "axial spondyloarthritis" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Hydrochlorothiazide, reaction(s): "known allergies". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 16Sep2022, outcome "unknown", described as "Moderna, Dose: 1-4 / Pfizer, Dose: 5"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Mar2023, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, COVID-19: the patient received Paxlovid from 20Mar2023 to 25Mar2023 for treatment of COVID-19.; Sender's Comments: Based on available information, a possible contributory role of the subject vaccine cannot be excluded for suspected LOE. There is limited information provided in this report. This case will be reassessed upon receipt of follow-up information.